Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample

被引:3
|
作者
Radestig, Maya Arvidsson [1 ,2 ]
Skoog, Ingmar [1 ,2 ,3 ]
Skillback, Tobias [1 ,2 ]
Zetterberg, Henrik [2 ,4 ,5 ,6 ,7 ]
Kern, Jurgen [1 ]
Zettergren, Anna [1 ,2 ]
Andreasson, Ulf [2 ,4 ]
Wetterberg, Hanna [1 ,2 ]
Kern, Silke [1 ,2 ,3 ]
Blennow, Kaj [2 ,4 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Neuropsychiat,Epidemiol Unit, Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden
[3] Sahlgrens Univ Hosp, Dept Psychiat Cognit & Old Age Psychiat, Gothenburg, Sweden
[4] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden
[5] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England
[6] UK Dementia Res Inst UCL, London WC1N 3BG, England
[7] Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China
基金
欧盟地平线“2020”; 美国国家卫生研究院; 欧洲研究理事会;
关键词
Alzheimer's disease; Cerebrospinal fluid; CSF; biomarkers; Neurolfilament light; NfL; Neurogranin; ALZHEIMERS-DISEASE; NEUROFILAMENT LIGHT; TAU; NEUROGRANIN; DEMENTIA; PROTEIN; BRAIN; A-BETA(1-42); ASSOCIATION; MARKER;
D O I
10.1186/s13195-023-01193-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundNeurofilament light (NfL) and neurogranin (Ng) are promising candidate AD biomarkers, reflecting axonal and synaptic damage, respectively. Since there is a need to understand the synaptic and axonal damage in preclinical Alzheimer's disease (AD), we aimed to determine the cerebrospinal fluid (CSF) levels of NfL and Ng in cognitively unimpaired elderly from the Gothenburg H70 Birth Cohort Studies classified according to the amyloid/tau/neurodegeneration (A/T/N) system.MethodsThe sample consisted of 258 cognitively unimpaired older adults (age 70, 129 women and 129 men) from the Gothenburg Birth Cohort Studies. We compared CSF NfL and Ng concentrations in A/T/N groups using Student's T-test and ANCOVA.ResultsCSF NfL concentration was higher in the A-T-N+ group (p=0.001) and the A-T+N+ group (p=0.006) compared with A-T-N-. CSF Ng concentration was higher in the A-T-N+, A-T+N+, A+T-N+, and A+T+N+ groups (p<0.0001) compared with A-T-N-. We found no difference in NfL or Ng concentration in A+ compared with A- (disregarding T- and N- status), whereas those with N+ had higher concentrations of NfL and Ng compared with N- (p<0.0001) (disregarding A- and T- status).ConclusionsCSF NfL and Ng concentrations are increased in cognitively normal older adults with biomarker evidence of tau pathology and neurodegeneration.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample
    Maya Arvidsson Rådestig
    Ingmar Skoog
    Tobias Skillbäck
    Henrik Zetterberg
    Jürgen Kern
    Anna Zettergren
    Ulf Andreasson
    Hanna Wetterberg
    Silke Kern
    Kaj Blennow
    Alzheimer's Research & Therapy, 15
  • [2] Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias
    Antonell, Anna
    Tort-Merino, Adria
    Rios, Jose
    Balasa, Mircea
    Borrego-Ecija, Sergi
    Auge, Josep M.
    Munoz-Garcia, Cristina
    Bosch, Beatriz
    Falgas, Neus
    Rami, Lorena
    Ramos-Campoy, Oscar
    Blennow, Kaj
    Zetterberg, Henrik
    Molinuevo, Jose L.
    Llado, Albert
    Sanchez-Valle, Raquel
    ALZHEIMERS & DEMENTIA, 2020, 16 (02) : 262 - 272
  • [3] Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
    Bloniecki, Victor
    Zetterberg, Henrik
    Aarsland, Dag
    Vannini, Patrizia
    Kvartsberg, Hlin
    Winblad, Bengt
    Blennow, Kaj
    Freund-Levi, Yvonne
    ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)
  • [4] Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
    Bos, Isabelle
    Vos, Stephanie
    Verhey, Frans
    Scheltens, Philip
    Teunissen, Charlotte
    Engelborghs, Sebastiaan
    Sleegers, Kristel
    Frisoni, Giovanni
    Blin, Olivier
    Richardson, Jill C.
    Bordet, Regis
    Tsolaki, Magda
    Popp, Julius
    Peyratout, Gwendoline
    Martinez-Lage, Pablo
    Tainta, Mikel
    Lleo, Alberto
    Johannsen, Peter
    Freund-Levi, Yvonne
    Froelich, Lutz
    Vandenberghe, Rik
    Westwood, Sarah
    Dobricic, Valerija
    Barkhof, Frederik
    Legido-Quigley, Cristina
    Bertram, Lars
    Lovestone, Simon
    Streffer, Johannes
    Andreasson, Ulf
    Blennow, Kaj
    Zetterberg, Henrik
    Visser, Pieter Jelle
    ALZHEIMERS & DEMENTIA, 2019, 15 (05) : 644 - 654
  • [5] Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease
    Thorsell, Annika
    Bjerke, Maria
    Gobom, Johan
    Brunhage, Eva
    Vanmechelen, Eugeen
    Andreasen, Niels
    Hansson, Oskar
    Minthon, Lennart
    Zetterberg, Henrik
    Blennow, Kaj
    BRAIN RESEARCH, 2010, 1362 : 13 - 22
  • [6] Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease
    Moore, Elizabeth E.
    Gifford, Katherine A.
    Khan, Omair A.
    Liu, Dandan
    Pechman, Kimberly R.
    Acosta, Lealani Mae Y.
    Bell, Susan P.
    Turchan, Maxim
    Landman, Bennett A.
    Blennow, Kaj
    Zetterberg, Henrik
    Hohman, Timothy J.
    Jefferson, Angela L.
    ALZHEIMERS & DEMENTIA, 2020, 16 (06) : 883 - 895
  • [7] Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia
    Mattsson, Niklas
    Ruetschi, Ulla
    Pijnenburg, Yolande A. L.
    Blankenstein, Marinus A.
    Podust, Vladimir N.
    Li, Susann
    Fagerberg, Inger
    Rosengren, Lars
    Blennow, Kaj
    Zetterberg, Henrik
    MOLECULAR MEDICINE REPORTS, 2008, 1 (05) : 757 - 761
  • [8] Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia
    Das, Shreyasee
    Goossens, Julie
    Jacobs, Dirk
    Dewit, Nele
    Pijnenburg, Yolande A. L.
    In't Veld, Sjors G. J. G.
    Teunissen, Charlotte E.
    Vanmechelen, Eugeen
    ALZHEIMERS RESEARCH & THERAPY, 2023, 15 (01)
  • [9] Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia
    Sogorb-Esteve, Aitana
    Nilsson, Johanna
    Swift, Imogen J.
    Heller, Carolin
    Bocchetta, Martina
    Russell, Lucy L.
    Peakman, Georgia
    Convery, Rhian S.
    van Swieten, John C.
    Seelaar, Harro
    Borroni, Barbara
    Galimberti, Daniela
    Sanchez-Valle, Raquel
    Laforce, Robert, Jr.
    Moreno, Fermin
    Synofzik, Matthis
    Graff, Caroline
    Masellis, Mario
    Tartaglia, Maria Carmela
    Rowe, James B.
    Vandenberghe, Rik
    Finger, Elizabeth
    Tagliavini, Fabrizio
    Santana, Isabel
    Butler, Chris R.
    Ducharme, Simon
    Gerhard, Alexander
    Danek, Adrian
    Levin, Johannes
    Otto, Markus
    Sorbi, Sandro
    Le Ber, Isabelle
    Pasquier, Florence
    Gobom, Johan
    Brinkmalm, Ann
    Blennow, Kaj
    Zetterberg, Henrik
    Rohrer, Jonathan D.
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [10] Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration
    Hoglund, Kina
    Schussler, Nathalie
    Kvartsberg, Hlin
    Smailovic, Una
    Brinkmalm, Gunnar
    Liman, Victor
    Becker, Bruno
    Zetterberg, Henrik
    Cedazo-Minguez, Angel
    Janelidze, Shorena
    Lefevre, Isabel A.
    Eyquem, Stephanie
    Hansson, Oskar
    Blennow, Kaj
    NEUROBIOLOGY OF DISEASE, 2020, 134